Santaris Pharma A/S and Pfizer Inc. announced that the companies have expanded their collaboration directed to the development and commercialization of RNA-targeted medicines using Santaris Pharma Locked Nucleic Acid (LNA) Drug Platform.

Under the terms of the expanded agreement, Pfizer will make a payment of $14 million for access to Santaris Pharma LNA technology for the development of RNA-targeted drugs. Santaris Pharma is eligible to receive milestone payments of up to $600 million as well as royalties on sales of products that may be developed for up to 10 new RNA targets selected by Pfizer. The newly expanded alliance builds on the original collaboration formed in January 2009 between Santaris Pharma A/S and Wyeth, which was acquired by Pfizer Inc.

Source:

Santaris Pharma A/S